17,800 Shares in CG Oncology, Inc. $CGON Acquired by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC purchased a new position in CG Oncology, Inc. (NASDAQ:CGON) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 17,800 shares of the company’s stock, valued at approximately $739,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in CG Oncology by 11.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after buying an additional 670,770 shares in the last quarter. Wellington Management Group LLP lifted its stake in CG Oncology by 190.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock valued at $222,055,000 after buying an additional 3,613,885 shares in the last quarter. Alliancebernstein L.P. lifted its stake in CG Oncology by 15.0% in the 2nd quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock valued at $56,270,000 after buying an additional 281,637 shares in the last quarter. Bank of America Corp DE lifted its stake in CG Oncology by 409.9% in the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock valued at $45,156,000 after buying an additional 1,396,170 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in CG Oncology by 2.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,349,527 shares of the company’s stock valued at $56,032,000 after buying an additional 30,960 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Trading Up 2.6%

Shares of CGON opened at $62.29 on Friday. The firm has a market capitalization of $5.49 billion, a P/E ratio of -26.73 and a beta of 0.41. The stock’s fifty day simple moving average is $66.91 and its 200 day simple moving average is $55.45. CG Oncology, Inc. has a twelve month low of $23.65 and a twelve month high of $75.50.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. Sell-side analysts predict that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Insider Activity at CG Oncology

In other news, Director James Mulay sold 15,600 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the transaction, the director owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on CGON shares. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of CG Oncology in a research note on Monday, May 18th. Wall Street Zen lowered CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Wolfe Research started coverage on CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. Finally, Truist Financial reissued a “buy” rating and set a $82.00 price target (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.73.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.